Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free HQL Stock Alerts

abrdn Life Sciences Investors (HQL) Competitors

abrdn Life Sciences Investors logo
$18.23 +0.04 (+0.19%)
Closing price 03:59 PM Eastern
Extended Trading
$18.19 -0.04 (-0.19%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

HQL vs. NUV, GAB, USA, STEW, and BCAT

Should you buy abrdn Life Sciences Investors stock or one of its competitors? MarketBeat compares abrdn Life Sciences Investors with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with abrdn Life Sciences Investors include Nuveen Municipal Value Fund (NUV), Gabelli Equity Trust (GAB), Liberty All-Star Equity Fund (USA), SRH Total Return Fund (STEW), and BlackRock Capital Allocation Term Trust (BCAT). These companies are all part of the "financial services" industry.

How does abrdn Life Sciences Investors compare to Nuveen Municipal Value Fund?

abrdn Life Sciences Investors (NYSE:HQL) and Nuveen Municipal Value Fund (NYSE:NUV) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

abrdn Life Sciences Investors has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Nuveen Municipal Value Fund has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

In the previous week, abrdn Life Sciences Investors had 4 more articles in the media than Nuveen Municipal Value Fund. MarketBeat recorded 4 mentions for abrdn Life Sciences Investors and 0 mentions for Nuveen Municipal Value Fund. abrdn Life Sciences Investors' average media sentiment score of 0.50 beat Nuveen Municipal Value Fund's score of 0.00 indicating that abrdn Life Sciences Investors is being referred to more favorably in the media.

Company Overall Sentiment
abrdn Life Sciences Investors Positive
Nuveen Municipal Value Fund Neutral

abrdn Life Sciences Investors pays an annual dividend of $1.91 per share and has a dividend yield of 10.5%. Nuveen Municipal Value Fund pays an annual dividend of $0.26 per share and has a dividend yield of 2.8%.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
abrdn Life Sciences Investors$86.39M6.42N/AN/AN/A
Nuveen Municipal Value Fund$60.75M31.27N/AN/AN/A

32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. Comparatively, 22.5% of Nuveen Municipal Value Fund shares are owned by institutional investors. 10.1% of abrdn Life Sciences Investors shares are owned by insiders. Comparatively, 1.0% of Nuveen Municipal Value Fund shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
abrdn Life Sciences InvestorsN/A N/A N/A
Nuveen Municipal Value Fund N/A N/A N/A

Summary

abrdn Life Sciences Investors beats Nuveen Municipal Value Fund on 7 of the 8 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to Gabelli Equity Trust?

abrdn Life Sciences Investors (NYSE:HQL) and Gabelli Equity Trust (NYSE:GAB) are both small-cap finance companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

abrdn Life Sciences Investors has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Gabelli Equity Trust has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
abrdn Life Sciences InvestorsN/A N/A N/A
Gabelli Equity Trust N/A N/A N/A

32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. Comparatively, 7.2% of Gabelli Equity Trust shares are owned by institutional investors. 10.1% of abrdn Life Sciences Investors shares are owned by insiders. Comparatively, 0.8% of Gabelli Equity Trust shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, abrdn Life Sciences Investors had 1 more articles in the media than Gabelli Equity Trust. MarketBeat recorded 4 mentions for abrdn Life Sciences Investors and 3 mentions for Gabelli Equity Trust. Gabelli Equity Trust's average media sentiment score of 0.92 beat abrdn Life Sciences Investors' score of 0.50 indicating that Gabelli Equity Trust is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
abrdn Life Sciences Investors
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Gabelli Equity Trust
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

abrdn Life Sciences Investors pays an annual dividend of $1.91 per share and has a dividend yield of 10.5%. Gabelli Equity Trust pays an annual dividend of $0.60 per share and has a dividend yield of 10.7%.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
abrdn Life Sciences Investors$86.39M6.42N/AN/AN/A
Gabelli Equity Trust$305.25M5.71N/AN/AN/A

Summary

abrdn Life Sciences Investors beats Gabelli Equity Trust on 5 of the 8 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to Liberty All-Star Equity Fund?

abrdn Life Sciences Investors (NYSE:HQL) and Liberty All-Star Equity Fund (NYSE:USA) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. Comparatively, 10.0% of Liberty All-Star Equity Fund shares are owned by institutional investors. 10.1% of abrdn Life Sciences Investors shares are owned by company insiders. Comparatively, 0.1% of Liberty All-Star Equity Fund shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

abrdn Life Sciences Investors pays an annual dividend of $1.91 per share and has a dividend yield of 10.5%. Liberty All-Star Equity Fund pays an annual dividend of $0.68 per share and has a dividend yield of 11.8%.

In the previous week, abrdn Life Sciences Investors had 4 more articles in the media than Liberty All-Star Equity Fund. MarketBeat recorded 4 mentions for abrdn Life Sciences Investors and 0 mentions for Liberty All-Star Equity Fund. abrdn Life Sciences Investors' average media sentiment score of 0.50 beat Liberty All-Star Equity Fund's score of 0.00 indicating that abrdn Life Sciences Investors is being referred to more favorably in the media.

Company Overall Sentiment
abrdn Life Sciences Investors Positive
Liberty All-Star Equity Fund Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
abrdn Life Sciences Investors$86.39M6.42N/AN/AN/A
Liberty All-Star Equity FundN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
abrdn Life Sciences InvestorsN/A N/A N/A
Liberty All-Star Equity Fund N/A N/A N/A

abrdn Life Sciences Investors has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Liberty All-Star Equity Fund has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Summary

abrdn Life Sciences Investors beats Liberty All-Star Equity Fund on 5 of the 7 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to SRH Total Return Fund?

SRH Total Return Fund (NYSE:STEW) and abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SRH Total Return FundN/AN/AN/AN/AN/A
abrdn Life Sciences Investors$86.39M6.42N/AN/AN/A

SRH Total Return Fund pays an annual dividend of $0.73 per share and has a dividend yield of 4.1%. abrdn Life Sciences Investors pays an annual dividend of $1.91 per share and has a dividend yield of 10.5%.

In the previous week, abrdn Life Sciences Investors had 3 more articles in the media than SRH Total Return Fund. MarketBeat recorded 4 mentions for abrdn Life Sciences Investors and 1 mentions for SRH Total Return Fund. abrdn Life Sciences Investors' average media sentiment score of 0.50 beat SRH Total Return Fund's score of 0.34 indicating that abrdn Life Sciences Investors is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SRH Total Return Fund
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
abrdn Life Sciences Investors
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
SRH Total Return FundN/A N/A N/A
abrdn Life Sciences Investors N/A N/A N/A

15.6% of SRH Total Return Fund shares are held by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are held by institutional investors. 0.1% of SRH Total Return Fund shares are held by insiders. Comparatively, 10.1% of abrdn Life Sciences Investors shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SRH Total Return Fund has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, abrdn Life Sciences Investors has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Summary

abrdn Life Sciences Investors beats SRH Total Return Fund on 6 of the 7 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to BlackRock Capital Allocation Term Trust?

abrdn Life Sciences Investors (NYSE:HQL) and BlackRock Capital Allocation Term Trust (NYSE:BCAT) are both small-cap financial services companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
abrdn Life Sciences Investors$86.39M6.42N/AN/AN/A
BlackRock Capital Allocation Term Trust$223.60M7.38N/AN/AN/A

abrdn Life Sciences Investors pays an annual dividend of $1.91 per share and has a dividend yield of 10.5%. BlackRock Capital Allocation Term Trust pays an annual dividend of $3.18 per share and has a dividend yield of 20.2%.

Company Net Margins Return on Equity Return on Assets
abrdn Life Sciences InvestorsN/A N/A N/A
BlackRock Capital Allocation Term Trust N/A N/A N/A

32.2% of abrdn Life Sciences Investors shares are held by institutional investors. Comparatively, 36.1% of BlackRock Capital Allocation Term Trust shares are held by institutional investors. 10.1% of abrdn Life Sciences Investors shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

abrdn Life Sciences Investors has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, BlackRock Capital Allocation Term Trust has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

In the previous week, abrdn Life Sciences Investors had 4 more articles in the media than BlackRock Capital Allocation Term Trust. MarketBeat recorded 4 mentions for abrdn Life Sciences Investors and 0 mentions for BlackRock Capital Allocation Term Trust. abrdn Life Sciences Investors' average media sentiment score of 0.50 beat BlackRock Capital Allocation Term Trust's score of 0.00 indicating that abrdn Life Sciences Investors is being referred to more favorably in the media.

Company Overall Sentiment
abrdn Life Sciences Investors Positive
BlackRock Capital Allocation Term Trust Neutral

Summary

BlackRock Capital Allocation Term Trust beats abrdn Life Sciences Investors on 5 of the 8 factors compared between the two stocks.

Get abrdn Life Sciences Investors News Delivered to You Automatically

Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HQL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HQL vs. The Competition

Export
Metricabrdn Life Sciences InvestorsFIN IndustryFinance SectorNYSE Exchange
Market Cap$554.19M$4.60B$13.47B$23.00B
Dividend Yield10.55%7.23%5.82%4.07%
P/E RatioN/A0.0223.1728.39
Price / Sales6.4249.17170.1339.98
Price / CashN/A5.5620.5025.11
Price / BookN/A4.582.154.76
Net IncomeN/A$388.27M$1.11B$1.06B
7 Day Performance1.53%0.20%-0.66%-0.75%
1 Month Performance2.56%0.72%0.57%1.73%
1 Year Performance52.00%15.69%11.19%25.04%

abrdn Life Sciences Investors Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HQL
abrdn Life Sciences Investors
N/A$18.23
+0.2%		N/A+50.0%$554.19M$86.39MN/AN/A
NUV
Nuveen Municipal Value Fund
N/A$9.19
+0.1%		N/A+5.6%$1.90BN/AN/A640
GAB
Gabelli Equity Trust
N/A$5.73
+1.0%		N/A-2.9%$1.78BN/AN/AN/A
USA
Liberty All-Star Equity Fund
N/A$5.85
+0.6%		N/A-14.2%$1.76BN/AN/AN/A
STEW
SRH Total Return Fund
N/A$17.72
+0.6%		N/A-0.6%$1.71B$177.28MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:HQL) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
Distracted Americans set to miss out on quadrillions
Technology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...
Brownstone Research | Sponsoredtc pixel